Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol
ISRCTN | ISRCTN77942127 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN77942127 |
Secondary identifying numbers | N/A |
- Submission date
- 08/09/2005
- Registration date
- 27/10/2005
- Last edited
- 11/10/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Matthew Walters
Scientific
Scientific
Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom
Phone | +44 (0)141 211 2821 |
---|---|
gcl203@clinmed.gla.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
Scientific title | Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol |
Study objectives | To investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension. |
Ethics approval(s) | West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1) |
Health condition(s) or problem(s) studied | Hypertension |
Intervention | Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Losartan, atenolol |
Primary outcome measure | Changes in cerebrovascular reactivity. |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 01/08/2004 |
Completion date | 01/02/2006 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Male |
Target number of participants | 13 |
Key inclusion criteria | 1. Male: 50-80 years 2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) 3. Blood pressure (BP) 150-200/90-115 |
Key exclusion criteria | 1. >70% internal carotid artery (ICA) stenosis 2. Middle cerebral artery (MCA) stenosis 3. Contra-indication to losartan, atenolol or acetazolamide 4. Serum creatinine >130 µmol/l 5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment |
Date of first enrolment | 01/08/2004 |
Date of final enrolment | 01/02/2006 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
Western Infirmary
Glasgow
G11 6NT
United Kingdom
G11 6NT
United Kingdom
Sponsor information
University of Glasgow (UK)
University/education
University/education
University Avenue
Glasgow
G11 6NT
Scotland
United Kingdom
Phone | +44 (0)141 211 2176 |
---|---|
pcn1w@clinmed.gla.ac.uk | |
https://ror.org/00vtgdb53 |
Funders
Funder type
University/education
University of Glasgow
Private sector organisation / Universities (academic only)
Private sector organisation / Universities (academic only)
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
11/10/2016: No publications found, verifying study status with principal investigator.